RNR

All (4) RNR Inhibitors (4)

Catalog No.	Information	Product Use Citations	Product Validations
S1218	Clofarabine Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.	Cancer Cell Int, 2020, 19;20:58 Nat Commun, 2019, 10(1):2189 EMBO J, 2018, 37(14)	Immunoblot analysis of cell lysates of NCI-H929 cells treated with CLO (5 μM, 3-48 h) GAPDH served as the loading control for each membrane, and data are representative of at least two independent experiments
S7470	Triapine Triapine (3-AP) is a potent ribonucleotide reductase (RNR) inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.	Nat Commun, 2020, 11(1):3214 Onco Targets Ther, 2020, 13:6523-6537 Onco Targets Ther, 2019, 12:3267-3275	(a) Quantification of p-RPA/ Rad51, 53BP1 and γH2AX in GBM01 cells treated with DMSO or triapine. (b) Quantification of p-RPA/Rad51, 53BP1 and γH2AX in GBM02 cells treated with DMSO or triapine.
S0283^New	COH-29 COH29 is a potent inhibitor of ribonucleotide reductase (RNR) with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50 of 16 μM.
S3641	Osalmid Osalmid suppresses ribonucleotide reductase (RNR) activity in a concentration-dependent manner, with a 50% RR activity-inhibitory concentration (IC50) of 8.23 μM.

Catalog No.	Information	Product Use Citations	Product Validations
S1218	Clofarabine Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.	Cancer Cell Int, 2020, 19;20:58 Nat Commun, 2019, 10(1):2189 EMBO J, 2018, 37(14)	Immunoblot analysis of cell lysates of NCI-H929 cells treated with CLO (5 μM, 3-48 h) GAPDH served as the loading control for each membrane, and data are representative of at least two independent experiments
S7470	Triapine Triapine (3-AP) is a potent ribonucleotide reductase (RNR) inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.	Nat Commun, 2020, 11(1):3214 Onco Targets Ther, 2020, 13:6523-6537 Onco Targets Ther, 2019, 12:3267-3275	(a) Quantification of p-RPA/ Rad51, 53BP1 and γH2AX in GBM01 cells treated with DMSO or triapine. (b) Quantification of p-RPA/Rad51, 53BP1 and γH2AX in GBM02 cells treated with DMSO or triapine.
S0283^New	COH-29 COH29 is a potent inhibitor of ribonucleotide reductase (RNR) with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50 of 16 μM.
S3641	Osalmid Osalmid suppresses ribonucleotide reductase (RNR) activity in a concentration-dependent manner, with a 50% RR activity-inhibitory concentration (IC50) of 8.23 μM.